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Origins of HIV and the AIDS Pandemic
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Acquired immunodeficiency syndrome (AIDS) of humans is caused by two lentiviruses,
human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2). Here, we describe the
origins and evolution of these viruses, and the circumstances that led to the AIDS pandemic.
Both HIVs are the result of multiple cross-species transmissions of simian immunodefi-
ciency viruses (SIVs) naturally infecting African primates. Most of these transfers resulted
in viruses that spread in humans to only a limited extent. However, one transmission
event, involving SIVcpz from chimpanzees in southeastern Cameroon, gave rise to HIV-1
group M—the principal cause of the AIDS pandemic. We discuss how host restriction
factors have shaped the emergence of new SIV zoonoses by imposing adaptive hurdles to
cross-species transmission and/or secondary spread. We also show that AIDS has likely
afflicted chimpanzees long before the emergence of HIV. Tracing the genetic changes that
occurred as SIVs crossed from monkeys to apes and from apes to humans provides a new
framework to examine the requirements of successful host switches and to gauge future
zoonotic risk.
Acquired Immune Deficiency Syndrome(AIDS) was first recognized as a new disease
in 1981 when increasing numbers of young
homosexual men succumbed to unusual op-
portunistic infections and rare malignancies
(CDC 1981; Greene 2007). A retrovirus, now
termed human immunodeficiency virus type 1
(HIV-1), was subsequently identified as the
causative agent of what has since become one
of the most devastating infectious diseases to
have emerged in recent history (Barre-Sinoussi
et al. 1983; Gallo et al. 1984; Popovic et al.
1984). HIV-1 spreads by sexual, percutaneous,
and perinatal routes (Hladik and McElrath
2008; Cohen et al. 2011); however, 80% of
adults acquire HIV-1 following exposure at
mucosal surfaces, and AIDS is thus primarily a
sexually transmitted disease (Hladik and McEl-
rath 2008; Cohen et al. 2011). Since its first
identification almost three decades ago, the
pandemic form of HIV-1, also called the main
(M) group, has infected at least 60 million
people and caused more than 25 million deaths
(Merson et al. 2008). Developing countries
have experienced the greatest HIV/AIDS
morbidity and mortality, with the highest
prevalence rates recorded in young adults in
sub-Saharan Africa (http://www.unaids.org/).
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Although antiretroviral treatment has reduced
the toll of AIDS- related deaths, access to
therapy is not universal, and the prospects of
curative treatments and an effective vaccine
are uncertain (Barouch 2008; Richman et al.
2009). Thus, AIDS will continue to pose a
significant public health threat for decades to
come.
Ever since HIV-1 was first discovered, the
reasons for its sudden emergence, epidemic
spread, and unique pathogenicity have been a
subject of intense study. A first clue came in
1986 when a morphologically similar but anti-
genically distinct virus was found to cause
AIDS in patients in western Africa (Clavel
et al. 1986). Curiously, this new virus, termed
human immunodeficiency virus type 2 (HIV-
2), was only distantly related to HIV-1, but
was closely related to a simian virus that
caused immunodeficiency in captive macaques
(Chakrabarti et al. 1987; Guyader et al.
1987). Soon thereafter, additional viruses,
collectively termed simian immunodeficiency
viruses (SIVs) with a suffix to denote their spe-
cies of origin, were found in various different
primates from sub-Saharan Africa, including
African greenmonkeys, sooty mangabeys, man-
drills, chimpanzees, and others (Fig. 1). Sur-
prisingly, these viruses appeared to be largely
nonpathogenic in their natural hosts, despite
clustering together with the human and simian
AIDS viruses in a single phylogenetic lineage
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Figure 1.Origins of human AIDS viruses. OldWorldmonkeys are naturally infected withmore than 40 different
lentiviruses, termed simian immunodeficiency viruses (SIVs) with a suffix to denote their primate species of
origin (e.g., SIVsmm from sooty mangabeys). Several of these SIVs have crossed the species barrier to great
apes and humans, generating new pathogens (see text for details). Known examples of cross-species transmis-
sions, as well as the resulting viruses, are highlighted in red.
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within the radiation of lentiviruses (Fig. 2).
Interestingly, close simian relatives of HIV-1
and HIV-2 were found in chimpanzees (Huet
et al. 1990) and sooty mangabeys (Hirsch
et al. 1989), respectively. These relationships
provided the first evidence that AIDS had
emerged in both humans and macaques as a
consequence of cross-species infections with
lentiviruses from different primate species
(Sharp et al. 1994). Indeed, subsequent studies
confirmed that SIVmacwas not a natural patho-
gen of macaques (which are Asian primates),
but had been generated inadvertently in US
primate centers by inoculating various species
of macaques with blood and/or tissues from
naturally infected sooty mangabeys (Apetrei
et al. 2005, 2006). Similarly, it became clear
that HIV-1 and HIV-2 were the result of zoo-
notic transfers of viruses infecting primates in
Africa (Hahn et al. 2000). In this article, we
summarizewhat is known about the simian pre-
cursors of HIV-1 and HIV-2, and retrace the
steps that led to the AIDS pandemic.
PRIMATE LENTIVIRUSES
Lentiviruses cause chronic persistent infec-
tions in various mammalian species, including
bovines, horses, sheep, felines, and primates.
The greatmajority of lentiviruses are exogenous,
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Figure 2. Phylogeny of lentiviruses. The evolutionary relationships among Pol sequences ( 770 amino acids)
derived from various mammalian lentiviruses; host species are indicated at the right. Exogenous viruses are
depicted in black, with HIV-1, HIV-2, and SIVmac highlighted in red; endogenous viruses are shown in purple.
The phylogenetic tree was estimated using maximum likelihood methods (Guindon and Gascuel 2003). The
scale bar represents 0.10 amino acid replacements per site.
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meaning that they are transmitted horizontally
between individuals. However, it has recently
become clear that, on several occasions in the
past, lentiviruses have infiltrated their hosts’
germlines and become endogenous, vertically
transmissible, genomic loci (Fig. 2). Examples
include the rabbit endogenous lentivirus type
K (RELIK), which became germ-line embedded
approximately 12 million years ago (Katzoura-
kis et al. 2007; van der Loo et al. 2009), and
two prosimian endogenous lentiviruses, which
independently invaded the germ-lines of both
the grey mouse lemur (pSIVgml) and the fat-
tailed dwarf lemur (pSIVfdl) about 4 million
years ago (Gifford et al. 2008; Gilbert et al.
2009). These “viral fossils” are of particular
interest because they provide direct evidence
of the timescale of lentivirus evolution. Molec-
ular clocks derived from extant SIV sequences
suggested that ancestral SIVs existed only a few
hundreds of years ago (Wertheim and Worobey
2009), but it has long been suspected that such
analyses may grossly underestimate deeper evo-
lutionary timescales (Sharp et al. 2000; Holmes
2003). Recent studies of SIV-infected monkeys
on Bioko Island, Equatorial Guinea, partly
substantiated this conclusion, showing that
geographically isolated subspecies have been
infected with the same type of SIV for at least
30,000 years and probably much longer (Woro-
bey et al. 2010). The endogenous viruses in
lemurs reveal that the span of evolutionary his-
tory of primate lentiviruses as a whole is at least
two orders of magnitude greater still. Thus, it is
possible that at least some SIVs, such as those
infecting four closely related species of African
green monkeys (Chlorocebus species), have
coevolved with their respective hosts for an
extended period of time, perhaps even before
these hosts diverged from their common ances-
tor (Jin et al. 1994a). So far, SIV infections have
only been found in African monkeys and apes,
and so it seems likely that primate lentiviruses
emerged in Africa sometime after the splits
between lineages of African and Asian Old
World monkeys, which are believed to have
occurred around 6–10 million years ago (Fabre
et al. 2009). However, because neither Asian
nor New World primates have been sampled
exhaustively, the conclusion that SIVs are
restricted to African primates must remain ten-
tative, especially because none of these primate
species has been examined for endogenous
forms of SIV (Ylinen et al. 2010). Thus, our
understanding of the evolutionary history of
primate lentiviruses is still incomplete.
To date, serological evidence of SIV infec-
tion has been reported for over 40 primate
species, and molecular data have been obtained
for most of these (also see Klatt et al. 2011). The
latter studies have shown that the great majority
of primate species harbor a single “type” or
“strain” of SIV. That is, viral sequences from
members of the same species form a monophy-
letic clade in evolutionary trees. This host-
specific clustering indicates that the greatmajor-
ity of transmissions occur among members of
the same species; however, there are also numer-
ous documented instances when SIVs have
crossed between species. Examples range from
incidental “dead-end” infections (e.g., SIVver
infections of baboons) (Jin et al. 1994b; van
Rensburg et al. 1998) to the generation of
new SIV lineages with substantial secondary
spread (e.g., SIVgor infection of gorillas) (Van
Heuverswyn et al. 2006). In addition, cross-spe-
cies transmissions have generated mosaic SIV
lineages through superinfection and recombi-
nation in species that already harbored an SIV
(e.g., SIVsab infection of sabaeus monkeys)
(Jin et al. 1994a). In bothmandrills (Mandrillus
sphinx) and moustached monkeys (Cercopithe-
cus cephus), such recombination events have led
to the emergence of a second SIV strain that
cocirculates with the original virus (Souquiere
et al. 2001; Aghokeng et al. 2007). Thus, it is
clear that in addition to more long-standing
virus/host relationships, a number of naturally
occurring SIVs have emerged more recently as
a result of cross-species transmission and re-
combination. What remains unknown is when
and how often these cross-species transfers
have occurred, what impact they had on virus
and host biology, and whether AIDS is a fre-
quent consequence of SIV host switching.
The prevalence of naturally occurring SIV infec-
tions varies widely, ranging from 1% in some
species to over 50% in others (Aghokeng et al.
P.M. Sharp and B.H. Hahn
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2010), and it is tempting to speculate that less
ubiquitous SIVs were acquired more recently
and/or may be more pathogenic.
ORIGIN AND DISTRIBUTION OF SIVcpz
Of the many primate lentiviruses that have been
identified, SIVcpz has been of particular inter-
est because of its close genetic relationship to
HIV-1 (Fig. 2). However, studies of this virus
have proven to be challenging because of the
endangered status of chimpanzees. The first
isolates of SIVcpz were all derived from ani-
mals housed in primate centers or sanctuaries,
although infection was rare in these popula-
tions. Collective analyses of nearly 2,000 wild-
caught or captive-born apes identified fewer
than a dozen SIVcpz positive individuals (Sharp
et al. 2005). Because other primate species, such
as sootymangabeys andAfrican greenmonkeys,
are much more commonly infected, both in
captivity and in the wild (Fultz et al. 1990;
Phillips-Conroy et al. 1994; Santiago et al.
2005), this finding raised doubts about whether
chimpanzees represented a true SIV reservoir.
To resolve this conundrum, our laboratory de-
veloped noninvasive diagnostic methods that
detect SIVcpz specific antibodies and nucleic
acids in chimpanzee fecal and urine samples
with high sensitivity and specificity (Santiago
et al. 2003; Keele et al. 2006). These technical
innovations, combined with genotyping meth-
ods for species and subspecies confirmation as
well as individual identification, permitted a
comprehensive analysis of wild-living chim-
panzee populations throughout central Africa.
Chimpanzees are classified into two species,
the common chimpanzee (Pan troglodytes) and
the bonobo (Pan paniscus). Common chimpan-
zees have traditionally been further subdivided
into a number of geographically differentiated
subspecies (Groves 2001). Four subspecies
were defined on the basis of mitochondrial
DNA sequences (Gagneux et al. 1999), namely
western (P. t. verus), Nigeria-Cameroonian
(P. t. ellioti, formerly termed P. t. vellerosus),
central (P. t. troglodytes), and eastern (P. t.
schweinfurthii) chimpanzees. To determine
the distribution of SIVcpz among these
populations, fecal (and in some cases urine)
samples were collected at different field sites
and tested for the presence of virus specific
antibodies. Antibody positive fecal specimens
were then subjected to RNA extraction and
reverse transcriptase polymerase chain reaction
(RT-PCR) amplification to molecularly charac-
terize the infecting virus strain. At select field
sites, mitochondrial and microsatellite analyses
of host DNA were also used to confirm sam-
ple integrity and to determine the number of
tested individuals. Figure 3A summarizes cur-
rent molecular epidemiological data derived
from the analysis of over 7,000 chimpanzee fecal
samples collected at nearly 90 field sites (San-
tiago et al. 2002, 2003; Worobey et al. 2004;
Keele et al. 2006; Van Heuverswyn et al. 2007;
Li et al. 2010; Rudicell et al. 2010). These studies
have identified common chimpanzees as a nat-
ural SIVcpz reservoir, but also revealed impor-
tant differences between the epidemiology of
SIVcpz and that of other primate lentiviruses.
First, only two of the four chimpanzee subspe-
cies were found to harbor these viruses. SIVcpz
was detected at multiple sites throughout the
ranges of both central and eastern chimpanzees
in an area ranging from Cameroon to Tanzania,
but there was no evidence of infection in west-
ern and Nigeria-Cameroonian chimpanzees,
nor in bonobos, despite testing of multiple
communities. In addition, SIVcpz prevalence
rates among central and eastern chimpanzees
varied widely, ranging from 30% to 50% in
some communities to rare or absent infection
in others. In contrast, other SIVs, such as those
of sootymangabeys andAfrican greenmonkeys,
are much more widely and evenly distributed
and infect their hosts at generally higher preva-
lence rates (Phillips-Conroy et al. 1994; San-
tiago et al. 2005). Nonetheless, the puzzle of
why SIVcpz was so scarce among captive
chimpanzees was finally resolved: As it turned
out, most of these apes were imported from
West Africa and thus were members of the
P. t. verus subspecies, which does not harbor
SIVcpz (Prince et al. 2002; Switzer et al. 2005).
The absence of SIVcpz from two of the four
subspecies suggested that chimpanzees had
acquired this virus more recently, after their
Origins of HIV and the AIDS Pandemic
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divergence into different subspecies. Indeed,
phylogenetic analyses of full-length proviral
sequences revealed that SIVcpz represents a
complex mosaic, generated by recombination
of two lineages of SIVs that infect monkeys
(Bailes et al. 2003). In the 50 half of the genome,
as well as the nef gene and 30 LTR, SIVcpz ismost
closely related to SIVrcm from red-cappedman-
gabeys (Cercocebus torquatus); however, in the
vpu, tat, rev, and env genes, SIVcpz is most
closely related to a clade of SIVs infecting several
Cercopithecus species, including greater spot-
nosed (C. nictitans), mustached (C. cephus),
and mona (C. mona) monkeys (Bailes et al.
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Figure 3.Geographic distribution of SIVcpz and SIVgor infections in sub-Saharan Africa. Field sites wherewild-
living (A) chimpanzees and bonobos, and (B) gorillas have been sampled are shown (each site is identified by a
two-letter code; because of space limitations, only a subset is depicted). Sites where SIV infections were detected
are highlighted in yellow. The upper panel depicts the ranges of the four subspecies of the common chimpanzee
(Pan troglodytes verus, gray; P. t. ellioti, magenta; P. t. troglodytes, red; and P. t. schweinfurthii, blue) and of the
bonobo (P. paniscus, orange). The lower panel depicts the ranges of western (Gorilla gorilla, green) and eastern
(G. beringei, brown) gorillas (map courtesy of Lilian Pintea, The Jane Goodall Institute). Data were compiled
from several studies (Santiago et al. 2002, 2003; Worobey et al. 2004; Keele et al. 2006; Van Heuverswyn et al.
2007; Li et al. 2010; Rudicell et al. 2010).
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2003). Chimpanzees are known to hunt and
kill othermammals, includingmonkeys (Good-
all 1986), suggesting that they acquired SIV
in the context of predation. The current range
of the central chimpanzee overlaps those of
red-cappedmangabeys and the variousCercopi-
thecus species, and so it is likely that the cross-
species transmission events that led to the
emergence of SIVcpz occurred in that area,
and that SIVcpz later spread to eastern chim-
panzees, although it is unclear whether this
occurred during or subsequent to their diver-
gence from the central subspecies. Importantly,
all of more than 30 sequenced SIVcpz strains
show an identical mosaic genome structure.
Moreover, there is no evidence that chimpan-
zees harbor any other SIV, although they, as
well as bonobos, are routinely exposed to SIVs
through their hunting behavior (Mitani and
Watts 1999; Surbeck and Hohmann 2008;
Leendertz et al. 2011).
NATURAL HISTORY OF SIVcpz INFECTION
Initially, SIVcpz was thought to be harmless for
its natural host. This was because none of the
few captive apes that were naturally SIVcpz
infected suffered from overt immunodeficiency,
although in retrospect this conclusion was
based on the immunological and virological
analyses of only a single naturally infected
chimpanzee (Heeney et al. 2006). In addition,
SIV-infected sooty mangabeys and African
green monkeys showed no sign of disease
despite high viral loads in blood and lymphatic
tissues (Paiardini et al. 2009), leading to the
belief that all naturally occurring SIV infections
are nonpathogenic. However, the sporadic
prevalence of SIVcpz, along with its more recent
monkeyorigin, suggested that its natural history
might differ from that of other primate lentivi-
ruses. To address this, a prospective study was
initiated in Gombe National Park, Tanzania,
the only field site where SIVcpz infected chim-
panzees are habituated and so can be observed
in their natural habitat.
Gombe is located in northwestern Tanzania
on the shores of Lake Tanganyika. The park is
home to three communities, termed Kasekela,
Mitumba, and Kalande, which have been
studied by Goodall and colleagues since the
1960s, 1980s, and 1990s, respectively (Pusey
et al. 2007). Prospective studies of SIVcpz in
Gombe began in 2000 (Santiago et al. 2002).
By 2009, infections were documented in all
three communities, with mean biannual preva-
lence rates of 13%, 12%, and 46% in Mitumba,
Kasekela, and Kalande, respectively (Rudicell
et al. 2010). Analysis of epidemiologically
linked infections revealed that SIVcpz spreads
primarily through sexual routes, with an esti-
mated transmission probability per coital act
(0.0008–0.0015) that is similar to that of
HIV-1 among heterosexual humans (0.0011)
(Gray et al. 2001; Rudicell et al. 2010). SIVcpz
also appears to be transmitted from infected
mothers to their infants, and in rare cases,
possibly by aggression (Keele et al. 2009).
Migration of infected females constitutes a
major route of virus transmission between
communities (Rudicell et al. 2010).
Behavioral and virological studies also
provided insight into the pathogenicity of
SIVcpz. Age-corrected mortality analyses re-
vealed that infected chimpanzees had a 10- to
16-fold increased risk of death compared to
uninfected chimpanzees (Keele et al. 2009).
SIVcpz-infected females were less likely to give
birth and had a much higher infant mortality
rate than uninfected females. Postmortem anal-
yses revealed significant CD4þ T-cell depletion
in three infected individuals, but not in either
of two uninfected individuals. One infected
female, who died within 3 years of acquiring
the virus, had histopathological findings consis-
tent with end-stage AIDS. Taken together, these
findings provided compelling evidence that
SIVcpz was pathogenic in its natural host. Sub-
sequent studies of both wild and captive chim-
panzees confirmed these findings. By the end
of 2010, the Kasekela and Mitumba commun-
ities had experienced three additional deaths,
all SIVcpz related. One case concerned an infant
born to an infected mother, whereas the other
two were adult females, one of whom died
with severe CD4þT cell depletionwithin 5 years
of acquiring SIVcpz (KA Terio et al., submit-
ted). Moreover, demographic studies revealed
Origins of HIV and the AIDS Pandemic
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that the Kalande community, which showed the
highest SIVcpz prevalence rates (40%–50%),
had suffered a catastrophic population decline,
whereas the sizes of the Mitumba and Kasekela
communities, which were infected at a much
lower level (12%–13%), remained stable
(Rudicell et al. 2010). It has been suggested
that only members of the P. t. schweinfurthii
subspecies, or more particularly the chimpan-
zees of Gombe, are susceptible to SIVcpz-asso-
ciated pathogenicity (Weiss and Heeney 2009;
Soto et al. 2010). However, a prospective study
of orphaned chimpanzees in Cameroon identi-
fied an SIVcpz infected P. t. troglodytes ape that
suffered from progressive CD4þ T cell loss,
severe thrombocytopenia, and clinical AIDS
(Etienne et al. 2011). Thus, it seems likely that
SIVcpz has a substantial negative impact on
the health, reproduction, and lifespan of all
chimpanzees that harbor SIVcpz in the wild.
ORIGIN AND DISTRIBUTION OF SIVgor
Noninvasive testing also led to the unexpected
finding of a new SIV lineage in wild-living
gorillas (Fig. 4). Analysis of  200 fecal sam-
ples from southern Cameroon identified several
HIV/SIVantibody positive gorillas, and ampli-
fication of viral sequences revealed the existence
of a new SIV lineage, termed SIVgor (Van Heu-
verswyn et al. 2006). This lineage fell within the
radiation of SIVcpz, clustering with strains from
P. t. troglodytes apes, suggesting that gorillas had
acquired SIVgor by cross-species infection from
sympatric chimpanzees (Fig. 4). Phylogenetic
analyses of full-length SIVgor sequences con-
firmed this conclusion, indicating that SIVgor
resulted from a single chimpanzee-to-gorilla
transmission event estimated to have occurred
at least 100 to 200 years ago (Takehisa et al.
2009). Subsequent screening of over 2500 fecal
samples from 30 field sites across central Africa
uncovered additional SIVgor infections, but
only in western lowland gorillas (Gorilla gorilla
gorilla) and not in eastern gorillas (Gorilla
beringei). Although virus-positive apes were
present at field sites more than 400 km apart,
only four such sites were identified, and preva-
lence rates in these communities did not exceed
5% (Fig. 3B). Thus, SIVgor appears to be much
less common in gorillas than SIVcpz is in chim-
panzees (Neel et al. 2010). Whether SIVgor is
more prevalent in communities in parts of
west central Africa that have not yet been tested
is not known. It is also unclear whether SIVgor
is pathogenic for its host, because there has been
no opportunity to study the natural history of
this infection in either captive or wild-living
gorillas. Finally, it remains a mystery how goril-
las acquired SIVgor, because they are herbivores
and do not hunt or kill other mammals. None-
theless, gorillas and chimpanzees feed in the
same forest areas, whichmust have led to at least
one encounter that allowed transmission.
ORIGINS OF HIV-1
HIV-1 has long been suspected to be of chim-
panzee origin (Gao et al. 1999); however, until
recently, the perceived lack of a chimpanzee
reservoir left the source of HIV-1 open to
question. These uncertainties have since been
resolved by noninvasive testing of wild-living
ape populations. It is now well established
that all naturally occurring SIVcpz strains fall
into two subspecies-specific lineages, termed
SIVcpzPtt and SIVcpzPts, respectively, that are
restricted to the home ranges of their respective
hosts (Figs. 3 and 4). Viruses from these two
lineages are quite divergent, differing at about
30%–50% of sites in their Gag, Pol, and Env
protein sequences (Vanden Haesevelde et al.
1996). Interestingly, population genetic studies
have shown that central and eastern chimpan-
zees are barely differentiated, calling into
question their status as separate subspecies
(Fischer et al. 2006; Gonder et al. 2011). How-
ever, the fact that they harbor distinct SIVcpz
lineages suggests that central and eastern chim-
panzees have been effectively isolated for some
time. In addition, molecular epidemiological
studies in southern Cameroon have shown
that SIVcpzPtt strains show phylogeographic
clustering, with viruses from particular areas
forming monophyletic lineages, and the dis-
covery of SIVgor has identified a second ape
species as a potential reservoir for human infec-
tion (Van Heuverswyn et al. 2006). Collectively,
P.M. Sharp and B.H. Hahn
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these findings have allowed the origins of HIV-1
to be unraveled (Keele et al. 2006; Van Heuvers-
wyn et al. 2007).
HIV-1 is not just one virus, but comprises
four distinct lineages, termed groups M, N, O,
and P, each of which resulted from an independ-
ent cross-species transmission event. Group M
was the first to be discovered and represents
the pandemic form of HIV-1; it has infected
millions of people worldwide and has been
found in virtually every country on the globe.
Group O was discovered in 1990 and is much
less prevalent than group M (De Leys et al.
1990; Gurtler et al. 1994). It represents less
than 1% of global HIV-1 infections, and is
largely restricted to Cameroon, Gabon, and
neighboring countries (Mauclere et al. 1997;
Peeters et al. 1997). Group N was identified in
LB70.05 MB897
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SIVgor
SIVcpzPts
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TAN5
TAN2
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HIV-1 M/F
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HIV-1 M/J
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Figure 4.HIV-1 origins. The phylogenetic relationships of representative SIVcpz, HIV-1, and SIVgor strains are
shown for a region of the viral pol gene (HIV-1/HXB2 coordinates 3887–4778). SIVcpz and SIVgor sequences
are shown in black and green, respectively. The four groups of HIV-1, each of which represents an independent
cross-species transmission, are shown in different colors. Black circles indicate the four branches where cross-
species transmission-to-humans has occurred.White circles indicate two possible alternative branches onwhich
chimpanzee-to-gorilla transmission occurred. Brackets at the right denote SIVcpz from P. t. troglodytes
(SIVcpzPtt) and P. t. schweinfurthii (SIVcpzPts), respectively. The phylogenetic tree was estimated using max-
imum likelihood methods (Guindon and Gascuel 2003). The scale bar represents 0.05 nucleotide substitutions
per site.
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1998 (Simon et al. 1998), and is even less prev-
alent than group O; so far, only 13 cases of
group N infection have been documented, all
in individuals from Cameroon (Vallari et al.
2010). Finally, group P was discovered in 2009
in a Cameroonian woman living in France
(Plantier et al. 2009). Despite extensive screen-
ing, group P has thus far only been identified
in one other person, also from Cameroon (Val-
lari et al. 2011). Although members of all of
these groups are capable of causing CD4þ
T-cell depletion and AIDS, they obviously differ
vastly in their distribution within the human
population.
Figure 4 depicts a phylogenetic tree of repre-
sentative HIV-1, SIVcpz, and SIVgor strains. It
shows that all four HIV-1 groups, as well as
SIVgor, cluster with SIVcpzPtt from central
chimpanzees, identifying this subspecies as the
original reservoir of both human and gorilla
infections. HIV-1 groups N and M are very
closely related to SIVcpzPtt strains from south-
ern Cameroon, indicating that they are of chim-
panzee origin. It has even been possible to trace
their ape precursors to particular P. t. troglodytes
communities. HIV-1 group N appears to have
emerged in the vicinity of the Dja Forest in
south-central Cameroon, whereas the pan-
demic form, group M, likely originated in an
area flanked by the Boumba, Ngoko, and
Sangha rivers in the southeastern corner of
Cameroon (Keele et al. 2006; Van Heuverswyn
et al. 2007). Existing phylogenetic data sup-
port a gorilla origin of HIV-1 group P, but
too few SIVgor strains have been characterized
to identify the region where this transmission
might have occurred. In contrast, the immedi-
ate source of HIV-1 groupO remains unknown,
because there are no ape viruses that are partic-
ularly closely related to this group (Fig. 4).
Thus, HIV-1 group O could either be of chim-
panzee or gorilla origin. Nonetheless, the fact
that group O and P viruses are more closely
related to SIVcpzPtt than to SIVcpzPts suggests
that both groups originated in west central
Africa, which is consistent with their current
distributions.
How humans acquired the ape precursors of
HIV-1 groups M, N, O, and P is not known;
however, based on the biology of these viruses,
transmission must have occurred through cuta-
neous or mucous membrane exposure to
infected ape blood and/or body fluids. Such
exposures occur most commonly in the context
of bushmeat hunting (Peeters et al. 2002).
Whatever the circumstances, it seems clear
that human–ape encounters in west central
Africa have resulted in four independent cross-
species transmission events. Molecular clock
analyses have dated the onset of the group M
and O epidemics to the beginning of the
twentieth century (Korber et al. 2000; Lemey
et al. 2004; Worobey et al. 2008). In contrast,
groups N and P appear to have emerged more
recently, although the sequence data for these
rare groups are still too limited to draw defini-
tive conclusions.
Eastern chimpanzees are endemically in-
fected with SIVcpzPts throughout central Africa
(Fig. 3A). Although prevalence rates have
not been determined for all field sites, the
P. t. schweinfurthii communities that have been
studied show infection rates that are very
similar to those found in P. t. troglodytes (Keele
et al. 2006, 2009; Rudicell et al. 2010). Given
that SIVcpzPtt strains have been transmitted
to gorillas and humans on at least five occasions,
it is striking that evidence of similar trans-
missions from eastern chimpanzees is lacking.
There are a number of possible explanations.
First, the risk of human exposure to SIVcpzPts
may be lower, perhaps because of differences
in the frequencies or types of human–ape
interactions in central and east Africa. Second,
SIVcpzPts infections of humans may have
occurred, but gone unrecognized, because
of limited human sampling and a lack of
lineage-specific serological tests. Finally, as
discussed below, SIVcpzPtt has evolved to over-
come human restriction factors, such as teth-
erin, which may pose a barrier to cross-species
transmission; because SIVcpzPts is highly diver-
gent from SIVcpzPtt, viruses from this lineage
may not have been able to adapt in the same
way. Although SIVcpzPtt and SIVcpzPts strains
replicate with similar kinetics in human CD4þ
T cells in vitro (Takehisa et al. 2007), such cul-
tures are unlikely to accurately recapitulate the
P.M. Sharp and B.H. Hahn
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conditions of viral replication and transmission
in vivo.
ORIGINS OF HIV-2
Since its first discovery, HIV-2 has remained
largely restricted toWest Africa, with its highest
prevalence rates recorded in Guinea-Bissau and
Senegal (de Silva et al. 2008). However, overall
prevalence rates are declining, and in most
West African countries HIV-2 is increasingly
being replaced by HIV-1 (van der Loeff et al.
2006; Hamel et al. 2007). Viral loads tend to
be lower in HIV-2 than HIV-1 infected individ-
uals, which may explain the lower transmission
rates of HIV-2 and the near complete absence of
mother-to-infant transmissions (Popper et al.
2000; Berry et al. 2002). In fact, most indi-
viduals infected with HIV-2 do not progress
to AIDS, although those who do, show clinical
symptoms indistinguishable fromHIV-1 (Row-
land-Jones and Whittle 2007). Thus, it is clear
that the natural history of HIV-2 infection
differs considerably from that of HIV-1, which
is not surprising given that HIV-2 is derived
from a very different primate lentivirus.
A sooty mangabey origin of HIV-2 was first
proposed in 1989 (Hirsch et al. 1989) and
subsequently confirmed by demonstrating that
humans in West Africa harbored HIV-2 strains
that resembled locally circulating SIVsmm
infections (Gao et al. 1992; Chen et al. 1996).
SIVsmm was found to be highly prevalent,
both in captivity and in thewild, and to be non-
pathogenic in its natural host (Silvestri 2005).
In a wild-living sooty mangabey community,
SIVsmmwas primarily found in higher-ranking
females, suggesting that virus infection had no
appreciable negative effect on reproductive be-
havior or success (Santiago et al. 2005). Finally,
the fact that sooty mangabeys are frequently
hunted as agricultural pests in many areas
of West Africa provided plausible routes of
transmission.
Since its first isolation, at least eight distinct
lineages of HIV-2 have been identified, each of
which appears to represent an independent
host transfer (Fig. 5). By analogy with HIV-1,
these lineages have been termed groups A–H,
although only groups A and B have spread
within humans to an appreciable degree. Group
A has been found throughout western Africa
(Damond et al. 2001; Peeters et al. 2003),
whereas group B predominates in Cote d’Ivoire
(Pieniazek et al. 1999; Ishikawa et al. 2001). All
other HIV-2 “groups” were initially identified
only in single individuals, suggesting that they
represent incidental infection with very limited
or no secondary spread. Of these, groups C, G,
and H have been linked to SIVsmm strains
from Cote d’Ivoire, group D is most closely
related to an SIVsmm strain from Liberia, and
groups E and F resemble SIVsmm strains from
Sierra Leone (Gao et al. 1992; Chen et al. 1996,
1997; Santiago et al. 2005). Because of their spo-
radic nature, groups C–Hhave been assumed to
represent “dead-end” transmissions. However,
a second divergent HIV-2 strain has recently
been placed in group F (Fig. 5). This virus was
identified in an immigrant in New Jersey, who
came from the same geographic area in Sierra
Leone where this lineage was first discovered
(Smith et al. 2008). Unlike the original index
case, the newly identified group F infection
was associated with reduced CD4 T cell counts
and high viral loads (Smith et al. 2008). It is
presently unknown whether group F has been
spreading cryptically in humans, or whether
the two group F viruses represents independent
transmissions from sooty mangabeys.
HOST-SPECIFIC ADAPTATIONS
HIVand SIV must interact with a large number
of host proteins to replicate in infected cells (Fu
et al. 2009; Ortiz et al. 2009). Because the com-
mon ancestor of Old World monkeys and apes
existed around 25 million years ago, the diver-
gence of these host proteins may pose an
obstacle to cross-species infection. In addition,
primates (including humans) encode a number
of host restriction factors, which have evolved as
part of their innate immune response to protect
against infection with a wide variety of viral
pathogens (Malim and Emerman 2008; Neil
and Bieniasz 2009; Kajaste-Rudnitski et al.
2010). Although viruses have, in turn, found
ways to antagonize these restriction factors,
Origins of HIV and the AIDS Pandemic
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these countermeasures are frequently species-
specific. Thus, a number of adaptive hurdles
have to be overcome before primate lentiviruses
can productively infect a new species.
The first evidence of host-specific adapta-
tion of HIV-1 came from an analysis of sites
in the viral proteome that were highly conserved
in the ape precursors of HIV-1, but changed—
in the same way—each time these viruses
crossed the species barrier to humans (Wain
et al. 2007). This analysis identified one site in
the viral matrix protein (Gag-30) that encoded
aMet in all known strains of SIVcpzPtt and SIV-
gor but switched to an Arg in the inferred ances-
tors of HIV-1 groups M, N, and O, and has
subsequently been conserved as a basic amino
acid (Arg or Lys) in most strains of HIV-1.
The fact that the same nonconservative amino
acid substitution occurred on each of the three
branches involving cross-species transmission
to humans suggested that this matrix residue
was under strong host-specific selection pres-
sure. This conclusion was subsequently con-
firmed by two additional observations. First,
it was found that a reciprocal transmission,
in which a chimpanzee was experimentally
infected with HIV-1, led to the reversion of
this host-specific signature; that is, a basic
residue at Gag-30 in HIV-1 changed back to a
Met on in vivo propagation in a chimpanzee
(Mwaengo and Novembre 1998). Second,
it was found that in chimpanzee CD4þ T
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Figure 5.HIV-2 origins. The phylogenetic relationships of representative SIVsmm and HIV-2 strains are shown
for a region of the viral gag gene (SIVmac239 coordinates 1191–1921). SIVsmmand SIVmac are shown in black;
the eight groups of HIV-2, each of which represents an independent cross-species transmission, are shown in
different colors. The phylogenetic tree was estimated using maximum likelihood methods (Guindon and Gas-
cuel 2003). The scale bar represents 0.05 nucleotide substitutions per site.
P.M. Sharp and B.H. Hahn
12 Cite this article as Cold Spring Harb Perspect Med 2011;1:a006841
w
w
w
.p
er
sp
ec
ti
ve
si
n
m
ed
ic
in
e.
o
rg
lymphocytes, a virus with a Met at position 30
replicated more efficiently that an otherwise
isogenic virus with a Lys at the same position,
whereas the opposite was true in human cells
(Wain et al. 2007). Interestingly, only one of
the two recently discovered HIV-1 group P
strains has switched from a Met to a Lys at
Gag-30 (Vallari et al. 2011). Although the struc-
ture of theHIV-1matrix protein has been deter-
mined (Hill et al. 1996), the function of the
amino acid at position 30 is not known, and it
remains to be determined why this site is under
such strong selection pressure.
The potential of an SIV to infect a new pri-
mate species is also influenced by its ability to
counteract different host restriction factors.
Three classes of restriction factors have been
shown to constitute barriers to SIV cross-
species transmission. These include (1) APO-
BEC3G (apolipoprotein B mRNA editing
enzyme catalytic polypeptide-like 3G), which
interferes with reverse transcription (Sheehy
et al. 2002); (2) TRIM5a (tripartite motif 5a
protein), which interferes with viral uncoating
(Stremlau et al. 2004); and (3) tetherin (also
termed BST-2 and CD317) which inhibits the
budding and release of virions from infected
cells (Neil et al. 2008). Of these, tetherin appears
to have had the greatest impact on the precur-
sors of HIV-1 and HIV-2 (Fig. 6). Tetherin is
comprised of a cytoplasmic amino-terminal
region, a trans-membrane domain, a coiled-
coiled extracellular domain, and a carboxy-
terminal glycosylphosphatidylinositol (GPI)
anchor (Fig. 6B). Recent studies have shown
that most SIVs use their Nef protein to remove
tetherin from the cell surface by targeting its
cytoplasmic domain (Jia et al. 2009; Zhang
et al. 2009). In contrast, HIV-1 (Neil et al.
2008; Van Damme et al. 2008) as well as SIVs
from greater spot-nosed, mona, moustached,
and Dent’s monkeys (Sauter et al. 2009; Schmo-
kel et al. 2011) use their Vpu protein to degrade
tetherin by binding to its membrane-spanning
domain (Iwabu et al. 2009; Rong et al. 2009).
Still other viruses use their envelope glycopro-
tein to interfere with tetherin, by interacting
with either its extracellular or its cytoplasmic
domain (Bour et al. 1996; Gupta et al. 2009;
Le Tortorec and Neil 2009; Serra-Moreno et al.
2011). These various antitetherin responses
appear to have emerged as a direct result of
host-specific selection pressures following cross-
species transmission (Sauter et al. 2009; Evans
et al. 2010; Lim et al. 2010).
Because of the constant onslaught of viral
pathogens, host restriction factors evolve rap-
idly (Sawyer et al. 2004, 2005; McNatt et al.
2009; Lim et al. 2010). Most notably, the human
tetherin gene differs from that of other apes by
a five-codon deletion in the region encoding
the cytoplasmic domain (Sauter et al. 2009).
Because Nef interacts with the cytoplasmic
domain of tetherin, this deletion rendered the
SIVcpz Nef protein inactive on transmission
to humans. Gorilla tetherin does not have this
deletion, and thus Nef continued to function
as a tetherin antagonist on transmission of
SIVcpz to gorillas (Fig. 6C). Thus, to facilitate
replication in humans, SIVcpz and SIVgor
had to find alternative routes to overcome teth-
erin. One option was to switch back to using
Vpu, as in their monkey ancestors (Fig. 6C).
However, this required that the SIVcpz and SIV-
gor Vpu proteins regained this function because
neither has antitetherin activity in chimpanzee
or humans cells. Not surprisingly, this was not
successful in all instances (Fig. 6C). When rep-
resentatives of each of the HIV-1 groups were
analyzed, only the Vpu proteins of group M
viruses showed potent antitetherin activity
(Sauter et al. 2009). Group O and P Vpu pro-
teins were completely inactive, whereas the
group N Vpu showed only marginal activity
(Sauter et al. 2009; Kirchhoff 2010). Moreover,
even the latter adaptation came at a cost,
because the group N Vpu lost its ability to
down-modulate CD4. Thus, of the four trans-
mitted ape viruses, only the precursor of
HIV-1 group M succeeded in mounting a full
antitetherin defense in human cells. It may
thus not be a coincidence that onlyHIV-1 group
M resulted in a global epidemic (Gupta and
Towers 2009; Sauter et al. 2009).
Like many other SIVs, SIVsmm does not
encode a vpu gene and uses its Nef protein to
combat tetherin. Thus, on transmission to
humans, SIVsmm had to overcome the same
Origins of HIV and the AIDS Pandemic
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hurdle of a cytoplasmic tail deleted human teth-
erin. In this case, the envelope glycoprotein
(gp41) was recruited as an alternative tetherin
antagonist (Le Tortorec and Neil 2009). How-
ever, this escape mechanism has thus far only
been observed for epidemic HIV-2 group A,
and it will be interesting to determine which,
if any, of the other HIV-2 groups have acquired
a similar antitetherin activity. It seems likely
that the cytoplasmic domain deletion in human
tetherin has represented a significant barrier to
SIV zoonoses, including those viruses that have
succeeded in infecting humans.
ORIGIN OF THE AIDS PANDEMIC
HIV-1 evolves around one million times faster
than mammalian DNA (Li et al. 1988; Lemey
et al. 2006), because the HIV-1 reverse tran-
scriptase is error prone and the viral generation
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B
Figure 6.Tetherin function and virus specific antagonism in different primate hosts. (A)Mechanismof restricted
virion release by tetherin; two alternative models are shown (for details, see Evans et al. 2010); (B) Viral antag-
onists of tetherin and their sites of interaction (indicated by arrows). Vpu associates with the trans-membrane
domain of tetherin, Nef targets the cytoplasmic domain, and Env interacts either with the extracellular or the
cytoplasmic domain (Kirchhoff 2010; Serra-Moreno et al. 2011). (C) Antitetherin function in HIV-1 and
HIV-2 and their immediate simian precursors. SIVcpz acquired vpu and nef genes from different sources, the
SIVgsn/mus/mon and SIVrcm lineages, respectively. During adaptation in chimpanzees, Nef (and not Vpu)
evolved to become an effective tetherin antagonist. SIVgor and SIVsmm also use Nef to counteract tetherin.
After transmission to humans, SIVcpz, SIVgor, and SIVsmm Nef were unable to antagonize human tetherin
because of a deletion in its cytoplasmic domain. HIV-1 group M adapted by regaining Vpu-mediated antite-
therin activity. The Nef and Vpu proteins of HIV-1 groups O and P remained poor tetherin antagonists. The
Vpu of HIV-1 group N gained modest antitetherin activity, but lost the ability to degrade CD4. HIV-2 group
A adapted by gaining Env-mediated antitetherin activity; whether HIV-2 groups B–H gained antitetherin func-
tion has not been tested. Proteins that are active against tetherin are highlighted in red, and those that are inactive
are shown in gray (adapted from Kirchhoff [2010] and reprinted, with permission, from Elsevier#2010).
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time is short (Ho et al. 1995; Wei et al. 1995).
This propensity for rapid genetic change has
provided a unique opportunity to gain insight
into when and where the AIDS pandemic had
its origin. Phylogenetic and statistical analyses
have dated the last common ancestor of HIV-1
group M to around 1910 to 1930, with narrow
confidence intervals (Korber et al. 2000; Woro-
bey et al. 2008). This indicates that after pan-
demic HIV-1 first emerged in colonial west
central Africa, it spread for some 50 to 70 years
before it was recognized. The probable location
of the early epidemic has also been identified.
Molecular epidemiological studies have indi-
cated that most, if not all, of the early diversifi-
cation of HIV-1 group M likely occurred in the
area around Kinshasa, then called Leopoldville.
All of the known HIV-1 groupM subtypes were
identified there, as well as additional lineages
that have remained restricted to this area (Vidal
et al. 2000). Leopoldville was also the place
where the earliest strains of HIV-1 group M
were discovered (Zhu et al. 1998; Worobey
et al. 2008). Genetic analysis of infected blood
and tissue samples collected from residents of
Kinshasa in 1959 and 1960, respectively,
revealed that HIV-1 had already diversified
into different subtypes by that time (Worobey
et al. 2008). Finally, demographic data indicate
that pandemic HIV-1 emerged at a time when
urban populations in west central Africa were
expanding (Worobey et al. 2008). Leopoldville
was the largest city in the region at that time
and thus a likely destination for a newly emerg-
ing infection. Moreover, rivers, which served as
major routes of travel and commerce at the
time, would have provided a link between the
chimpanzee reservoir of HIV-1 group M in
southeastern Cameroon and Leopoldville on
the banks of the Congo (Sharp and Hahn
2008). Thus, all current evidence points to Leo-
poldville/Kinshasa as the cradle of the AIDS
pandemic.
As HIV-1 group M spread globally, its dis-
semination involved a number of population
bottlenecks—founder events, which led to the
predominance of different group M lineages,
now called subtypes, in different geographic
areas. HIV-1 group M is currently classified
into nine subtypes (A–D, F–H, J, K), as well
as more than 40 different circulating recom-
binant forms (CRFs), which were generated
when multiple subtypes infected the same pop-
ulation (Taylor et al. 2008). It has been possible
to trace themigration pathways of some of these
subtypes and CRFs. For example, subtypes A
and D originated in central Africa, but ulti-
mately established epidemics in eastern Africa,
whereas subtype C was introduced to, and pre-
dominates in, southern Africa from where it
spread to India and other Asian countries.
Subtype B, which accounts for the great major-
ity of HIV-1 infections in Europe and the
Americas, arose from a single African strain
that appears to have first spread to Haiti in the
1960s and then onward to the US and other
western countries (Gilbert et al. 2007). The
recombination event that created CRF01 prob-
ably occurred in Central Africa, but this viral
lineage was first noted in the late 1980s causing
a heterosexual epidemic in Thailand, contem-
porary with subtype B viruses spreading among
intravenous drug users (Taylor et al. 2008).
CRF01 has gone on to dominate the AIDS epi-
demic in southeast Asia. Although the initial
distribution of these subtypes and CRFs may
have been largely caused by chance events,
recent studies have suggested that viruses of dif-
ferent subtypes vary in their biological proper-
ties, which may influence their epidemiology
(Taylor et al. 2008). For example, subtype D
has been associated with greater pathogenicity
(Kiwanuka et al. 2010) and an increased inci-
dence of cognitive impairment and AIDS
dementia (Sacktor et al. 2009). It thus appears
that not only the genetic but also the biological
diversity ofHIV-1 groupM subtypes and CRF is
increasing.
CONCLUSIONS
Although primate lentiviruses were first identi-
fied in the late 1980s, it is only very recently
that the complexities of their evolutionary ori-
gins, geographic distribution, prevalence, natu-
ral history, and pathogenesis in natural and
nonnatural hosts have been appreciated. The
preceding sections summarize what is known
Origins of HIV and the AIDS Pandemic
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about the origins and evolution of the simian
relatives of HIV-1 and HIV-2, their propensity
to cross species barriers, and the host factors
that govern such transmissions. Given that there
are numerous additional primate species that
harbor SIV, the question arises what to expect
from future zoonoses? Host-specific restriction
factors play a major role in preventing cross-
species transmission, and they may well be
responsible for the fact that only two types of
SIV have thus far succeeded in colonizing
humans. However, as exemplified by the various
HIV-1 and HIV-2 outbreaks, they are certainly
not insurmountable. Determining the entire
spectrum of host restriction factors and their
mechanisms of action will be required to gauge
the likelihood of future zoonoses. In this regard,
the role of tetherin should be examined further.
Because this protein “tethers” virions to the cell
surface, a lack of effective antitetherin measures
may result in reduced titers of infectious virus in
genital secretions. This may explain why the
precursors of the rare groups of HIV-1 and
HIV-2 were able to infect humans but unable
to establish epidemic infections.
From the above, it is also clear that any
newly introduced SIV must replicate to some
extent to accumulate the necessary mutations
that are required to adapt to divergent host pro-
teins and restriction factors. Circumstances that
enhance human-to-human passage would thus
be expected to increase the chance of such adap-
tation. It has been suggested that large-scale
injection campaigns conducted in west central
Africa at the beginning of the twentieth century
(Pepin et al. 2006, 2010; Pepin and Labbe 2008),
together with the destabilization of social struc-
tures (Chitnis et al. 2000), the rapid growth of
cities (Worobey et al. 2008), and an increased
prevalence in sexually transmitted diseases,
including genital ulcers (de Sousa et al. 2010),
may have facilitated the early dissemination
and adaptation of both HIV-1 and HIV-2. The
fact that HIV-1 groups M and O as well as
HIV-2 group A all emerged around the same
time is consistent with this hypothesis (Korber
et al. 2000; Lemey et al. 2003, 2004; Worobey
et al. 2008; de Sousa et al. 2010). However,
whether these medical interventions and/or
social factors really played a role in the
emergence of HIV-1 and HIV-2, and more
importantly, whether such “jump-starts” were
required to spawn the AIDS pandemic, will
remain unknown.
Finally, it is important to view the patho-
genesis of simian and human AIDS viruses
in the context of their evolution (Kirchhoff
2009). One feature of pathogenic HIV-1 and
HIV-2 infection that distinguishes them from
nonpathogenic SIV infections is a high level of
chronic immune activation, which is a strong
predictor of disease progression. In HIV-1
infection, this immune activation is fueled, at
least in part, by the inability of the Nef protein
to down-modulate TCR-CD3, a function that
is conserved in most nonpathogenic SIV infec-
tions (Schindler et al. 2006; Arhel and Kirchhoff
2009). Lack of this Nef function is associated
with increased T-cell activation and apoptosis
in vitro and loss of CD4þ T cells in natural
SIV infection in vivo (Schindler et al. 2008). A
higher state of T- cell activation is associated
with enhanced levels of proviral transcription
and viral replication, but also with increased
expression of interferon-induced restriction
factors, such as tetherin. In HIV-1, Vpu com-
pensates for this by providing potent antite-
therin activity. It has thus been proposed that
to overcome the barriers of cross-species trans-
mission, primate lentiviruses must induce an
inflammatory milieu to increase their ability
to replicate and accumulate mutations neces-
sary for more adaptation (Kirchhoff 2009). If
this were indeed the case, AIDS would be an
inevitable consequence of SIV cross-species
transmission.
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